Covid-19: When will a vaccine be ready?

Development Status and Success Probabilities

• Global teams are racing to develop a vaccine, with hundreds of volunteers entering late-stage clinical trials.
• Russia claims to have won the race, though the success probability for current late-stage vaccines is approximately 80%.
• Novel technologies used in some candidates may introduce higher risks of failure than traditional methods.
• It remains uncertain which specific vaccines will work across different populations (e.g., efficacy in the elderly vs. prevention of transmission).
• There is a non-negligible chance that no single "silver bullet" vaccine will emerge.

Manufacturing, Timeline, and Supply Constraints

• Full global vaccination is projected to take at least two years, even if a successful vaccine is available by year-end.
• Experts estimate production of approximately 2 billion doses by the end of 2021, insufficient for the entire global population.
• Supply may be further constrained if multiple doses are required per person for immunity.
• Future pandemics could benefit from pre-established global vaccine manufacturing capacity to accelerate development upon viral genetic code publication.

Economic Impact and Financial Implications

• The global economy is currently losing between $200 billion and $250 billion weekly due to the pandemic.
• Accelerating vaccine availability by even a single day generates billions in economic benefits.
• Some pharmaceutical companies have committed to selling vaccines at cost (non-profit) for the first year.
• Industry participants argue that successful developers should be permitted to generate significant profits as an incentive for rapid innovation.
• Government-funded financial incentives for vaccination uptake may be economically viable given the high societal benefit.

Pricing, Access, and Distribution Models

• Final vaccine costs are undisclosed due to confidential government-companies agreements; estimates range from a few dollars to tens of dollars per dose.
• Production costs are uncertain due to the novelty of the technologies involved.
• In most countries, vaccines are expected to be distributed free of charge to recipients.
• Rich nations are urged to financially support vaccine procurement for developing countries to ensure equitable access.
• The GAVI (Global Alliance for Vaccines) mechanism is proposed as a vehicle for wealthy nations to fund vaccines for the poor world.

Vaccine Uptake and Ethical Challenges

• Achieving herd immunity requires approximately 70% vaccination coverage among the population or vulnerable subgroups.
• Misinformation and concerns over rushed development pose significant risks to vaccine acceptance, particularly in the United States where only ~50% of respondents indicated definite willingness to vaccinate.
• Ethical distribution protocols prioritize healthcare/social care workers first, followed by the elderly and those with chronic conditions.
• Historical precedents, such as the 2009 swine flu pandemic, suggest developing nations risk being left behind if wealthy nations hoard supplies.
• A significant portion of the global population may remain unvaccinated for years if manufacturing remains concentrated in specific countries that restrict exports.

Long-term Immunization Outlook

• It is unclear whether the virus will mutate requiring periodic new vaccine versions similar to influenza strains.
• The duration of immunity from the current vaccine candidates remains unknown.